arrow
I

Igor T. Gavrilovic

Memorial Sloan Kettering Cancer Center
H指数:23
被引数:3,989

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CERN 09-02: A Phase 2 Trial of Carboplatin and Bevacizumab for Recurrent Adult Ependymomas

CERN 09-02:卡铂和贝伐珠单抗治疗复发成人室管膜瘤的二期临床试验

2026-03-090
OA
Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma

伊布替尼联合利妥昔单抗、甲氨蝶呤、长春新碱和丙卡巴肼治疗新诊断的原发性中枢神经系统淋巴瘤

2026-03-010
PRE
Outcomes of inpatient chemoradiotherapy for patients with newly diagnosed glioblastoma and significant functional impairment

新诊断胶质母细胞瘤伴显著功能损害患者住院化放疗的结局

2026-01-010
OA
PHASE IB STUDY OF COPANLISIB, A PAN PI3K INHIBITOR, IN COMBINATION WITH IBRUTINIB, A BTK INHIBITOR, IN RELAPSED OR REFRACTORY PRIMARY CNS LYMPHOMA

I期B研究:评估泛PI3K抑制剂copanlisib与BTK抑制剂ibrutinib联合治疗复发或难治性原发性中枢神经系统淋巴瘤的疗效。

2025-11-010
OAAI
CERN 09-02: A PHASE 2 TRIAL OF CARBOPLATIN AND BEVACIZUMAB FOR RECURRENT ADULT EPENDYMOMA

CERN 09-02:一项关于卡铂和贝伐珠单抗治疗复发性成人室管膜瘤的II期临床试验

2025-11-010
OAAI
IBRUTINIB IN COMBINATION WITH RITUXIMAB, METHOTREXATE (MTX), VINCRISTINE, AND PROCARBAZINE (R-MPV/I) FOR NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA (PCNSL)

伊布替尼联合利妥昔单抗、甲氨蝶呤(MTX)、长春新碱和丙卡巴肼(R-MPV/I)用于新诊断的原发性中枢神经系统淋巴瘤(PCNSL)

2025-11-010
OAAI
Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma

多中心篮式试验针对中枢神经系统肿瘤,确定了CDK4/6抑制剂abemaciclib在复发性脑膜瘤中的活性

2025-10-010
PRE
Prospective characterization of germline variants in patients with gliomas and glioneuronal tumors

胶质瘤和神经胶质神经元肿瘤患者胚系变异的前瞻性表征

2025-09-120
OAAI
Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma

Ib期研究:在复发/难治性中枢神经系统淋巴瘤患者中扩大伊布替尼、来那度胺和利妥昔单抗的应用

2025-06-010
PRE
Immune Checkpoint Inhibitor Therapy for Aggressive Pituitary Neuroendocrine Tumors

免疫检查点抑制剂疗法治疗侵袭性垂体神经内分泌肿瘤

2025-03-200
OA
PROSPECTIVE GERMLINE SEQUENCING OF PATIENTS WITH GLIOMAS, GLIONEURONAL OR NEURONAL TUMORS
2024-11-110
PRE
Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics
2022-05-2313
OA
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

larotrectinib在TRK融合阳性原发性中枢神经系统肿瘤中的疗效和安全性

2021-11-2794
OAAI
Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling
2021-06-0129
OAAI
Clinical trial of proton craniospinal irradiation for leptomeningeal metastases
2020-06-2767
OAAI